

BIOMARIN PHARMACEUTICAL INC

Form 4

December 03, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Mueller Brian

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
105 DIGITAL DRIVE
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2014

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
VP, Corporate Controller

NOVATO, CA 94949
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2014	12/01/2014	M		521	A	\$ 14.39 (2)
Common Stock	12/01/2014	12/01/2014	M		6,429	A	\$ 21.51 (2)
Common Stock	12/01/2014	12/01/2014	S		6,950	D	\$ 90.25 (1)
Common Stock	12/02/2014	12/02/2014	M		5,000	A	\$ 28.23

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

						(2)		
						\$		
Common Stock	12/02/2014	12/02/2014	S	5,000	D	91.82	4,593	D
						(2)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	\$ 14.39	12/01/2014	12/01/2014	M	521	11/12/2009 ⁽³⁾ 05/11/2019	Common Stock	521	
Stock Option (right to buy Common Stock)	\$ 21.51	12/01/2014	12/01/2014	M	6,429	11/12/2010 ⁽⁵⁾ 05/11/2020	Common Stock	6,429	
Stock Option (right to buy Common Stock)	\$ 28.23	12/02/2014	12/02/2014	M	5,000	11/30/2011 ⁽⁶⁾ 05/31/2021	Common Stock	5,000	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Mueller Brian 105 DIGITAL DRIVE NOVATO, CA 94949			VP, Corporate Controller	

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

12/03/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) All shares sold at same price

The price in column 4 is a weighted average price. The price actually received ranged from \$91.74 to \$91.90. The reporting person will

(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

(3) Original option grant vests 6/48th on November 12, 2009, and 1/48th on the 12th day of every month thereafter.

(4) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

(5) Original option grant vests 6/48th on November 12, 2010, and 1/48th on the 12th day of every month thereafter.

(6) Original option grant vests 6/48th on November 30, 2011, and 1/48th on the 11th day of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.